ESTRO 2025 - Abstract Book

S823

Clinical - Gynaecology

ESTRO 2025

Results: After a median follow-up of 26 months (range 6-54), 2-year overall-survival, local-relapse-free-survival, pelvic relapse-free-survival (PRFS) and metastasis-free-survival rates were 93.8%, 100%, 96.8%, and 91.5%, respectively. PRFS was worse in G3 vs. G1-2 tumors (89.8% vs 100%, p=0.03), and p53-mutated tumors compared to wild-type (83.1% vs 100%, p=0.01). No patients experienced grade 3-4 toxicity. Grade 1-2 gastrointestinal and urinary toxicities were as follows: diarrhea 9.5%, proctitis and rectorragia 1.4%, hematuria 1%, pollakiuria 5%, and urgency/incontinence 20%. No significant association was found between toxicity and treatment modality (EBRT vs IGBT).